Search results for: Multi-Indication Medicines
Filter search results
OHE at ISPOR Europe 2024
17 November 2024, 8:00am
…November 2024 Title Name Time Type Are There More Optimal Approaches to Managing Pricing and Reimbursement of Multi-Indication Medicines to Better Facilitate Patient Access? Amanda Cole (panelist) 10:15-11:15 Issue Panel…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
…usage of new medical innovations because of low initial price per unit. Better pricing strategies for multi-indication products; rewards, rather than prices, would be linked to value. Solving patent protection…
A Critique of Hill et al. (2018) on Estimated Costs of Production for the WHO Essential Medicines List
19 May 2018
…reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018) in which the authors argue for “greater transparency…
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
1 August 2011
…prices for new medicines. From January 2014, the existing Pharmaceutical Pricing Regulation Scheme (PPRS) will be replaced by “value based pricing” (VBP) for branded medicines sold to the NHS. This…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
…problem will, in many markets, require the adoption of some form of indication or multi-use pricing. A valid value attribution process will help to enable this. Therefore, it is in…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
…entry and competition between multiple suppliers of equivalent or similar therapeutic alternatives. For example, tendering mechanisms should aim to avoid using a winner-takes-all design and promote approaches with multiple winners…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…accepted pricing models in Europe represents a barrier to their access. Drawing learnings from multi-indication pricing, we propose the adoption of strategies that support combination-based differential pricing (CBDP). We outline…
Incorporating Multiple Criteria in HTA
19 April 2011
…The authors argue for greater use of multiple criteria decision analysis (MCDA) as an aid to decision-making that is based on health technology assessment. What a health care system should…
Biosimilars and HTA: Results of a Roundtable Discussion
9 April 2014
…an OHE literature review and ABPI’s position paper on biosimilar medicines. The published Briefing focuses primarily on discussion about recommendation five from the ABPI position paper: ‘Biosimilar medicines should be…